ANIP

ANI Pharmaceuticals (ANIP) is highlighted as a stock with strong potential to beat upcoming earnings estimates. The company has demonstrated a consistent track record of earnings surprises, with an average surprise of 35.05% over the past two quarters. With a positive Earnings ESP of +6.45% and a Zacks Rank #3 (Hold), the stock shows indicators suggesting another earnings beat is likely.

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could beat their upcoming quarterly earnings estimates. ANI Pharmaceuticals (ANIP) has a +6.45% ESP ahead of its November 6, 2026 earnings release, while Regeneron (REGN) has a +0.23% ESP before reporting on October 30, 2026. Both stocks carry a Zacks Rank #3 (Hold) rating, and the article suggests that stocks with positive ESP combined with a Zacks Rank #3 or better have historically beaten earnings 70% of the time.

The article explains how to identify medical stocks poised for earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) tool. It highlights that combining a positive ESP with a Zacks Rank #3 or better has historically produced 70% positive surprises and 28.3% average annual returns. Two medical stocks are featured as examples: Solventum (SOLV) with a +2.81% ESP and ANI Pharmaceuticals (ANIP) with a +6.45% ESP, both expected to report earnings in early November 2026.